Interest in the potential of monoclonal antibodies (mAbs) to serve as therapeutic agents has surged in the past decade with a major emphasis on human viral diseases. There has been much attention in this area directed towards the human immunodeficiency virus type-1 (HIV-1) and promising research developments have emerged on the inhibition of HIV-1 infection by mAbs and the identification of several highly conserved neutralizing epitopes. More recently, potent fully-human neutralizing mAbs have been developed against a variety of important human viral disease agents including the paramyxoviruses Hendra virus and Nipah virus, and human or humanized mAbs have been developed against severe acute respiratory syndrome coronavirus (SARS CoV), and West Nile virus, among others. Most of these more recently developed antiviral mAbs have come from the use of antibody phage-display technologies and the implementation of simplified, inexpensive yet efficient methods, for expressing and purifying the initially selected fragment antibodies is of prime importance in further facilitating this area of research.
Introduction
Interest in the potential of monoclonal antibodies (mAbs) as therapeutic agents has surged in the past decade. Currently, however, the main therapeutic targets of antibodies remain cancer and autoimmune diseases (1, 2) and only one antibody targeting viral infection, Synagis (palivizumab), has been approved by FDA for prophylaxis against respiratory syncytial virus (3) . Recently, potent neutralizing human monoclonal antibodies have been selected against the emerging paramyxoviruses Hendra virus and Nipah virus (4) which are now being evaluated in vivo for efficacy in a ferret model. Newly discovered human mAbs against the human immunodeficiency virus type-1 (HIV-1) have been developed which target highly conserved epitopes on the HIV-1 envelope glycoprotein and have not demonstrated any affinity to human proteins or lipids (5) . In addition, humanized or fully human mAbs have been selected against severe acute respiratory syndrome coronavirus (SARS CoV) (6) and West Nile virus (7) , among others (8) . Perhaps among the most significant advances in facilitating the development of specific antiviral mAbs has been the implementation of bacterial phage-display platforms using combinatorial antibody libraries (9, 10) . Such phage libraries can be prepared to encode human antibodies as fragment antibodies (Fabs) containing the light chain and the first two domains of the heavy chain. To meet increasing research needs, the implementation of new methods for expressing and purifying these recombinant antibodies is of primary importance to facilitate their efficient production while decreasing production costs.
The recombinant antibody production methods usually consist of three major steps: transformation, expression, and purification. In the transformation step, plasmid DNA coding for a His-tagged Fab is transformed into HB2151 bacterial cells, and successfully transformed cells are selected using ampicillin. During this step, Fab expression is suppressed by a high glucose concentration in the medium. In the next step, isopropyl -D-1-thiogalactopyranoside (IPTG) in the absence of glucose is used to induce Fab expression. In the purification step, Polymyxin B is used to release the Fab from the bacterial periplasm. Finally, Ni-NTA affinity chromatography is used to specifically purify the His-tagged Fab. In addition to the use of such mAbs as antivirals, these Fabs can serve as important tools as specific detection reagents in various other techniques, such as enzyme-linked immunosorbent assays (ELISA), western blots, immunoprecipitation, and flow cytometry analysis.
For research purposes it is often convenient to express and purify these Fabs in smaller amounts. However, quite often the quantities of these Fabs are insufficient for other purposes and there is necessity of rapid methods for their expression and purification. Here, we have devised such a rapid method, in which at first a stock of monoclonal recombinant phage harboring the plasmid (phagemid) encoding the desired Fab is prepared and then this phage is used for a multiple rapid Fab expression and purification procedure.
Materials

Preparation of Recombinant
Monoclonal Phage 1. TG1 competent cells (Stratagene, San Diego, CA).
2.
Plasmid DNA: Phagemid encoding the Fab clone, which has been selected against specific antigen from a phage library (see Note 1).
3. SOC medium: 20 g/l tryptone (Bacto, Voigt Global Distribution, Lawrence, KS), 5 g/l yeast extract (Bacto, Voigt Global Distribution), 0.5 g/l NaCl, 10 mM MgCl 2 , 10 mM MgSO 4 , 0.4% (w/v) glucose in water.
4. 2YT medium: 10 g/l yeast extract (Bacto, Voigt Global Distribution), 16 g/l tryptone (Bacto, Voigt Global Distribution), and 5 g/l NaCl in deionized water. Autoclave and store at room temperature for no longer than 1 month.
5.
Supplemented 2YT agar plates: 15 g/l Select agar (Invitrogen, Carlsbad, CA) and 10 g/l glucose in 2YT medium. Autoclave. When the medium cools down to about 45°C but not solidified, add 100 mg/ml ampicillin (Sigma, St. Louis, MO). Pour 20 ml per 9-cm plate (BD Biosciences, San Jose, CA), and store plates at 4°C for no longer than 1 month. 2. Resuspend the pellet in 15 ml of Polymyxin B-supplemented PBS. Transfer the suspension into 50 ml centrifuge tubes.
3. Shake for 30 min at room temperature to lyse the cells. This can be done using an orbital rotator or a shaker (see Note 5).
4.
Centrifuge the lysate at 22,000 g for 30 min at 4°C, and transfer the supernatant to a clean 50 ml Falcon tube. Discard the pellet.
5.
During the centrifugation, prepare the purification column. The column must be stabilized on the lab bench in a convenient position, with a container underneath to collect the waste products prior to elution. Add 500 ml Ni-NTA resin to the empty purification column at this point. Incubate on ice for at least 1 h before using for transformation, or store in 30 ml aliquots at -80°C for later use.
3. Measure the OD 280 of prepared phage stock, usual dilution for this measurement is 20 times. OD 280 $ 1.0 corresponds to 2.33 Â 10 12 phages.
4. The volume of medium inoculated in the expression step can be increased up to 300 ml per column used in the purification step. If inoculating a larger volume of medium, increase the volume of Ni-NTA agarose placed in the column by 100 ml per 50 ml increase in culture used.
Alternatively, instead of manually resuspending and then shaking/rotating for 30 min at room temperature, one can shake/ rotate for 1 h at room temperature. If using an orbital rotator, be sure to stabilize the tubes properly so that a rotation speed of at least 150 rpm can be used. At the end of the shaking or rotating, the pellet should be completely resuspended.
6. The first portion usually yields a slightly higher concentration, and it may be useful to elute the two portions into separate tubes in order to see the difference. However, the concentrations are seldom very different, and the two portions may be eluted together instead.
